Format

Send to

Choose Destination
See comment in PubMed Commons below
Mol Cell. 2013 Jul 25;51(2):236-48. doi: 10.1016/j.molcel.2013.05.003. Epub 2013 Jun 6.

The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling.

Author information

1
Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.

Erratum in

  • Mol Cell. 2013 Jul 25;51(2):273.

Abstract

The tricarboxylic acid cycle enzyme fumarate hydratase (FH) has been identified as a tumor suppressor in a subset of human renal cell carcinomas. Human FH-deficient cancer cells display high fumarate concentration and ROS levels along with activation of HIF-1. The underlying mechanisms by which FH loss increases ROS and HIF-1 are not fully understood. Here, we report that glutamine-dependent oxidative citric acid cycle metabolism is required to generate fumarate and increase ROS and HIF-1 levels. Accumulated fumarate directly bonds the antioxidant glutathione in vitro and in vivo to produce the metabolite succinated glutathione (GSF). GSF acts as an alternative substrate to glutathione reductase to decrease NADPH levels and enhance mitochondrial ROS and HIF-1 activation. Increased ROS also correlates with hypermethylation of histones in these cells. Thus, fumarate serves as a proto-oncometabolite by binding to glutathione which results in the accumulation of ROS.

PMID:
23747014
PMCID:
PMC3775267
DOI:
10.1016/j.molcel.2013.05.003
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center